Sorbonne University - UPMC Univ Paris 06, Ecole Normale Supérieure, PSL Research University, Département de Chimie, CNRS UMR 7203 LBM, 4 Place Jussieu, 75005 Paris, France.
Section des Sciences Pharmaceutiques (EPGL), University of Geneva, University of Lausanne, rue Michel Servet 1, 1211 Geneva 4, Switzerland.
Eur J Pharm Sci. 2017 Nov 15;109:169-181. doi: 10.1016/j.ejps.2017.07.026. Epub 2017 Jul 25.
The synthetic coumestrol derivative 6,12-dihydro-3-methoxy-1-benzopyrano[3,4-b][1,4]benzothiazin-6-one (estrothiazine, ESTZ) has been identified as a weak estrogen receptor α (ERα) ligand unable to compete with tritiated estradiol. The biological activity of this compound, supported by a methoxy group in position 3, seems mainly to result from its capacity to activate ERα dimerization without any participation of coactivators. In support of this view and referring to conventional estrogens, an ESTZ metabolism study conducted with hepatic human microsomes failed to provide any argument in favour of an estrogenic activity dependent on a metabolic conversion of the compound into hydroxylated metabolites with strong receptor activation ability. Interestingly, we failed to detect any oxidation of the sulfur atom of the compound. In the light of pharmacological literature data concerning sulfonylation, we assessed ERα-mediated activities generated by two sulfonylated ESTZ derivatives in which the methoxy group that plays a key role in its mechanism of action was maintained or removed. Sulfonylated ESTZ, even in its demethoxylated form, induced ERE-mediated transcriptions in MCF-7 breast cancer cells, without affecting the ERα turnover rate. In contrast to ESTZ, this compound failed to enhance the proliferation of ERα-positive breast cancer cells, suggesting that its sulfone function confers upon the receptor a capacity to elicit some of the known characteristics associated with estrogenic responses. Moreover, we demonstrated that this sulfone may contribute to ERα dimerization without any requirement of the methoxy group. Nevertheless, it seems to cooperate with this group, as reflected by a weak ability of the sulfonylated form of ESTZ to compete with tritiated estradiol for ERα-binding. Assessment of the docking of this compound within the ligand-binding domain of the receptor by molecular dynamics provided an explanation for this observation since the sulfone is engulfed in a small hydrophobic pocket involving the residues Leu-346, Leu-349, Ala-350 and Leu-384, also known to recruit coactivators. This work not only reports the sulfone functional group as a pharmacophore for estrogenic activity, but also opens new perspectives for the development of estrogenic molecules with therapeutic purpose and devoid of proliferative side effects.
合成的香豆雌酚衍生物 6,12-二氢-3-甲氧基-1-苯并吡喃[3,4-b][1,4]苯并噻嗪-6-酮(雌硫嗪,ESTZ)已被鉴定为一种弱雌激素受体 α(ERα)配体,无法与氚标记的雌二醇竞争。该化合物的生物学活性得到了 3 位甲氧基的支持,似乎主要源于其激活 ERα 二聚化的能力,而无需任何共激活剂的参与。支持这一观点,并参考传统雌激素,用肝人微粒体进行的 ESTZ 代谢研究未能提供任何论据支持其雌激素活性依赖于化合物代谢转化为具有强受体激活能力的羟基化代谢物。有趣的是,我们未能检测到化合物中硫原子的任何氧化。根据有关磺酰化的药理学文献数据,我们评估了两种磺酰化 ESTZ 衍生物产生的 ERα 介导的活性,其中在其作用机制中起关键作用的甲氧基被保留或去除。磺酰化 ESTZ,即使在去甲氧基形式下,也能诱导 MCF-7 乳腺癌细胞中 ERE 介导的转录,而不影响 ERα 周转率。与 ESTZ 相反,该化合物未能增强 ERα 阳性乳腺癌细胞的增殖,表明其磺酰基功能赋予受体引发一些与雌激素反应相关的已知特征的能力。此外,我们证明该磺酰基无需甲氧基即可促进 ERα 二聚化。然而,它似乎与该基团合作,这反映在 ESTZ 的磺酰化形式与氚标记的雌二醇竞争 ERα 结合的能力较弱。通过分子动力学评估该化合物在受体配体结合域内的对接,为这一观察结果提供了一个解释,因为磺酰基被包含 Leu-346、Leu-349、Ala-350 和 Leu-384 残基的小疏水性口袋吞没,这些残基也已知招募共激活剂。这项工作不仅报告了磺酰基官能团作为雌激素活性的药效基团,而且为开发具有治疗目的且无增殖副作用的雌激素分子开辟了新的前景。